title: Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
abstract: OBJECTIVE
  (18)F-Fluorodeoxyglucose ((18)F-FDG), (18)F-fluoro-3'-deoxy-3'-L-fluorothymidine ((18)F-FLT), (18)F-fluoromisonidazole ((18)F-FMISO), and (18)F-AlF-NOTA-PRGD2 ((18)F-RGD) are all commonly used PET tracers for tumor diagnosis based on different mechanisms of tissue uptake. This study compared the ex-vivo biodistribution and PET/computed tomography (CT) imaging studies of these four PET tracers in a xenograft prostate tumor-bearing mouse model.
  
  
  METHODS
  Nude mice were inoculated with 5 × 10 PC-3 cells in the right armpit. The ex-vivo biodistribution of (18)F-FDG, (18)F-FLT, (18)F-FMISO, and (18)F-RGD at 30, 60, 90, and 120 min after injection was compared. Micro-PET/CT images of (18)F-FDG, (18)F-FLT, and (18)F-RGD were acquired at 60 min, whereas (18)F-FMISO images were acquired at 90 min after injection.
  
  
  RESULTS
  The tumors were clearly visualized by micro-PET/CT using all four PET tracers. Ex-vivo biodistribution results showed highest tumor accumulation and tumor-to-muscle ratio of (18)F-FDG at each time point, accompanied by physiologically high uptakes in the brain, heart, and intestinal tract. Modest uptake of (18)F-FLT and (18)F-FMISO in tumors was observed at 60 and 90 min after injection, with less interference from other tissues compared with (18)F-FDG. Besides, (18)F-RGD also exhibited high tumor specificity; however, relatively low uptake was observed in the tumor.
  
  
  CONCLUSIONS
  Our results demonstrated the potential of (18)F-FMISO and (18)F-FLT in the diagnosis of xenograft prostate cancer.
authors.affiliation: aPET/CT of Imaging Department, Sichuan Cancer Hospital bNational Engineering Research Center for Biomaterials cDepartment of Radiology, West China Hospital, Sichuan University, Chengdu dThe Third People's Hospital of Chengdu, Chengdu eWuxi Molecular Imaging CRO Co. Ltd, Wuxi, People's Republic of China.
authors.forename: Zhuzhong
authors.initials: Z
authors.lastname: Cheng
authors.forename: Renbo
authors.initials: R
authors.lastname: Wei
authors.forename: Changqiang
authors.initials: C
authors.lastname: Wu
authors.forename: Haomiao
authors.initials: H
authors.lastname: Qing
authors.forename: Xiao
authors.initials: X
authors.lastname: Jiang
authors.forename: Hao
authors.initials: H
authors.lastname: Lu
authors.forename: Shirong
authors.initials: S
authors.lastname: Chen
authors.forename: Xinping
authors.initials: X
authors.lastname: Li
authors.forename: Guohui
authors.initials: G
authors.lastname: Xu
authors.forename: Hua
authors.initials: H
authors.lastname: Ai
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic; D015224:Dideoxynucleosides / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006571:Heterocyclic Compounds / Q000737:chemistry*; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008920:Misonidazole / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D064847:Multimodal Imaging; D009842:Oligopeptides / Q000737:chemistry*; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed
chemical_list: D015224:Dideoxynucleosides; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C031843:fluoromisonidazole; D019788:Fluorodeoxyglucose F18; C048993:1,4,7-triazacyclononane-N,N',N''-triacetic acid; C047981:arginyl-glycyl-aspartic acid; D008920:Misonidazole; C002854:alovudine